Company Overview
TAKE LIMITED, together with its subsidiaries, provides domain-intensive services in life sciences and software and information technology in India. The company offers clinical research, generics development, data sciences, regulatory affairs, and pharmacovigilance and safety services backed by technology expertise. It also provides embed digital and employ mobile solutions for patient centricity insight in life science sector; and payer solutions, including access to billing insight through cloud adoption. In addition, the company offers payer-provider digital solution, which includes personalized medicine, wellness, and patient engagement; and medical device solution, such as technological transformation with chip level programming, DICOM devices, wearables, PROM, nano devices, and miOTs. The company was formerly known as TAKE Solutions Limited and change its name to TAKE LIMITED in June 2026. TAKE LIMITED was incorporated in 2000 and is based in Chennai, India.
Why Investors Should Care
Generates a return on equity of 16.5%, reflecting efficient use of shareholder capital.
Return on capital employed stands at 15.4%.
Net profit has compounded at 36.9% per year over the last five years.
Maintains a net profit margin of 20.0%.
Carries low leverage with a debt-to-equity ratio of 0.00.
Recent Developments
- Trailing 12 Months Year-on-year growth — earnings -71.0%.
- 5-Year Trend Long-term compounding — revenue CAGR -34.1%, profit CAGR 36.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -34.07% |
| 1 Year: | - |
Compounded Profit Growth
| 5 Years: | 36.94% |
| 1 Year: | -71.04% |
Stock Price Performance
| 1 Year: | +139.85% |
| 6 Months: | -46.53% |
| 3 Months: | -36.16% |
| 1 Month: | -6.37% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)45.68 · Neutral
P/E of 76.59 is above the sector median of 35.94 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Excellent profit margin of 20.0%.
- Profit CAGR of 36.9% over 5 years.
CONS
- Trading at a high P/E of 76.6.
- Revenue declined at -34.1% CAGR over 5 years.
- Trading 55.7% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | TAKE TAKE LIMITED NSEPHARMA | 22.21 | 76.59 | ₹324.77 Cr | 0.00% | 15.37% | 16.52% | -34.07% | 36.94% |
| 2 | APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA | 8,974.50 | 66.71 | ₹1.29 L Cr | 0.22% | 19.79% | 21.50% | 15.33% | 33.34% |
| 3 | ALKEM Alkem Laboratories Limited NIFTY_MIDNSEPHARMA | 5,597.50 | 29.07 | ₹66,926.51 Cr | 0.35% | 18.56% | 17.56% | 8.30% | 32.74% |
| 4 | ABBOTINDIA Abbott India Limited NIFTY_MIDNSEPHARMA | 27,855.00 | 38.12 | ₹59,189.93 Cr | 1.89% | 41.87% | 34.46% | 9.01% | 17.80% |
| 5 | ANTHEM ANTHEM BIOSCIENCES LTD NIFTY_MIDNSEPHARMA | 825.65 | 81.26 | ₹46,377.90 Cr | 0.24% | 26.77% | 19.45% | 26.20% | 15.39% |
| 6 | AJANTPHARM Ajanta Pharma Limited NIFTY_MIDNSEPHARMA | 3,470.40 | 38.28 | ₹43,357.66 Cr | 1.86% | 29.41% | 23.33% | 13.40% | 21.55% |
| 7 | AGARWALEYE DR AGARWALS HEALTH CARE L NSEPHARMA | 532.30 | 127.96 | ₹16,875.30 Cr | 0.00% | 9.74% | 6.58% | 26.96% | 12.28% |
| 8 | APLLTD Alembic Pharmaceuticals Limited NSEPHARMA | 834.45 | 23.67 | ₹16,402.21 Cr | 1.49% | 12.77% | 12.36% | 9.46% | 25.42% |
| 9 | ALIVUS Alivus Life Sciences Limited NSEPHARMA | 1,325.20 | 27.06 | ₹16,265.43 Cr | 0.38% | 21.78% | 16.94% | 7.61% | 6.53% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in INR.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 54.19 Cr |
| Cost of Revenue | 0 | 0 | 0 | 0 | 54.20 Cr |
| Gross Profit | 0 | 0 | 0 | 0 | -1.42 L |
| Operating Expenses | 2.90 Cr | 1.15 Cr | 77.60 L | 35.13 L | 81.06 L |
| Operating Income | -2.90 Cr | -1.15 Cr | -77.60 L | -35.13 L | -82.48 L |
| EBITDA | 5.63 Cr | 55.80 L | -73.30 L | 1.11 Cr | 4.36 Cr |
| Interest Expense | 72.60 L | 24.40 L | 17.50 L | 9,000 | 0 |
| Pretax Income | 4.89 Cr | 30.40 L | -91.00 L | 1.11 Cr | 4.36 Cr |
| Tax Provision | 0 | 0 | 0 | 0 | 0 |
| Net Income | 47.68 Cr | -4.88 Cr | -91.00 L | 1.11 Cr | 4.36 Cr |
| Diluted EPS | 3.26 | -0.33 | -0.06 | 0.07 | 0.29 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | - | 189.07 Cr | 3.60 Cr | 0 | 54.19 Cr |
| Cost of Revenue | - | 83.01 Cr | 3.15 Cr | 0 | 54.20 Cr |
| Gross Profit | - | 106.06 Cr | 45.30 L | 0 | -1.42 L |
| Operating Expenses | - | 100.24 Cr | 6.97 Cr | 7.52 Cr | 1.91 Cr |
| Operating Income | - | 5.82 Cr | -6.52 Cr | -7.52 Cr | -1.92 Cr |
| EBITDA | - | -21.34 Cr | -52.22 Cr | 2.74 Cr | 4.77 Cr |
| Interest Expense | - | 7.10 Cr | 2.27 Cr | 1.96 Cr | 34.89 L |
| Pretax Income | - | -45.27 Cr | -62.37 Cr | 73.80 L | 4.42 Cr |
| Tax Provision | - | 1.68 Cr | 4.01 Cr | 0 | 16.00 L |
| Net Income | - | -100.27 Cr | -119.62 Cr | 37.47 Cr | 10.85 Cr |
| Diluted EPS | - | -6.86 | -8.18 | 2.53 | 0.74 |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Total Assets | - | 224.38 Cr | 88.11 Cr | 36.48 Cr | 36.24 Cr |
| Current Assets | - | 90.19 Cr | 35.28 Cr | 23.55 Cr | 23.77 Cr |
| Cash & Equivalents | - | 10.72 Cr | 84.50 L | 3.37 Cr | 25.96 L |
| Inventory | - | 77.60 L | 79.60 L | 0 | 0 |
| Receivables | - | 30.04 Cr | 7.04 Cr | 0 | 21.81 L |
| Total Liabilities | - | 115.78 Cr | 96.98 Cr | 15.95 Cr | 5.24 Cr |
| Current Liabilities | - | 100.90 Cr | 89.16 Cr | 15.95 Cr | 5.24 Cr |
| Long Term Debt | - | 5.76 Cr | 75.00 L | 0 | 0 |
| Total Debt | - | 46.37 Cr | 37.09 Cr | 0 | 0 |
| Total Equity | - | 108.60 Cr | -8.87 Cr | 20.53 Cr | 31.00 Cr |
| Shares Outstanding | - | 14.79 Cr | 14.79 Cr | 14.79 Cr | 14.79 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 20.02 Cr | 9.32 Cr | -16.37 Cr | -4.13 Cr |
| Investing Cash Flow | - | -2.12 Cr | -7.46 Cr | 22.21 Cr | 1.74 Cr |
| Financing Cash Flow | - | -35.72 Cr | -11.73 Cr | -3.24 Cr | -72.36 L |
| Capital Expenditure | -31.21 Cr | -32.40 Cr | -7.92 Cr | - | - |
| Free Cash Flow | - | -12.38 Cr | 1.40 Cr | -16.37 Cr | -4.13 Cr |
| Net Change in Cash | - | -17.83 Cr | -9.88 Cr | 2.60 Cr | -3.11 Cr |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Margin % | - | 56.1% | 12.6% | - | -0.0% |
| Operating Margin % | - | 3.1% | -181.0% | - | -3.5% |
| Net Margin % | - | -53.0% | -3,320.9% | - | 20.0% |
| ROE % | - | -92.3% | 1,348.1% | 182.5% | 35.0% |
| ROCE % | - | 4.7% | 619.9% | -36.6% | -6.2% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for TAKE
SpaceX shares rise even as company insiders get a chance to sell for the first time - ABC News - Breaking News, Latest News and Videos
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxNYlloamFaZU1fcGhTLWJiMVJjWWFTc2JydXJfOTliQVZZeHhNMDRNamNYcFhEcFpJOE9RajRJamV4WkU4d3MwLWxoY1piRThxV0xKYTF1b0pGckkwVjg4MHZpT1RPRW1md25UUHZqVzFVeWY0MFdacm8tOEhFVmUwcnFsUXJUUmlWS05pZj…
New partnership expands mentoring and scholarships for Orange County students - WFTV
<a href="https://news.google.com/rss/articles/CBMi3AFBVV95cUxNOVVvRkIyY2l2S1YwTVRMZGE2U3Zvck5DZk9Qb3l4TFp3OGZMaVhRbWRDQ0JtWG0tZUw1VGs1aF9veFBJTzV4TjNFWTlvR2pmVzZVaHVvdVROMVhMY0luWHdPbnhQQWNFXzZIdDJhMVB4WlhMWnhyR01SYmdQQmF2bktBRkxLaWE4QmJtSW…
Fiserv Shares Take a Sharp Dive After Disappointing Q2 Results and Guidance Cut - StockInvest.us
<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxNZ2dLR0dmamtBeDE5eWluRENab3FQa3ZXRFdBY2MtSk14S0FqYVRMd0hkS0licE9hNFVBS01feHJaMWtIMVN1aFR5cjVoc3FOeGI3cUw5ZTN3d3B1RVQyNm5JYjVZekh5c1lhay1fRHJRSHhNWC1fMTdaN3JlakNSTko5aG1YZU5xblRNNX…
Here’s How Much You Would Have Made Owning Take-Two Interactive Stock In The Last 15 Years - benzinga.com
<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxQVFpkUFVqMmkxa0hPM0hLTnJnZkRhZVhDUFZLWl9QajlsV1JnSGVQSDJfeVRnWEdPc0lzYnlOYkl3bGRKX2Rsd09QbmNRSlRxMnlwNEt3d25yX1AwMUFCZ2g4VWcwclpxNVY1OE14ZmU4RnJLdTNZelJrd1pvSmF4MFRoTmhmSDFfQU5SdF…
SpaceX is down nearly 40% ahead of Tuesday's earnings—how to decide to buy stock dips, according to pros - CNBC
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxPMkNVSXN1bHFVeDRoOWgwemtUOFNnS0ZBbTZici1vS21teGJMeVJFMEZSNmdqZGllbEcyZk9nMTBSTkhwTjVUWkRQdVFqdVA4LS1idDY5cG9SU0VpZ0U3QXJUSmFKaWd6RG5JZUI2Y1lLeE80Q1p4VG9fYkdadEtxSDVLSy0zS2lkRnV3Sl…
ADBE Stock: Where Compounding Could Take The Price - Trefis
<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxPQTJtYXVjcTkwZ1hOVC04TzhiZDkwZ2NaTDlrOVFnWmY3am5zZ2U4OW9ZNVNiTmxlR2lFbEZOV04tUjRqcTk0VDRlRDV2b2NvcVVXZUJfZzRyNG5aenFvbXdmenZOcFVTaXJhcFhNbG9sMGlkSGVQcVZkWTlhNTlBcGZuNTFtTU5FR2RMQm…
TAKE — Frequently Asked Questions
What is the current share price of TAKE LIMITED (TAKE)?
As of 2026-08-07 06:31 IST, TAKE LIMITED (TAKE) trades at ₹22.21 on NSE. Its 52-week range is ₹9.00 to ₹50.14.
What is the market capitalisation of TAKE?
TAKE LIMITED (TAKE) has a market capitalisation of ₹324.77 Cr on NSE.
What is the P/E ratio of TAKE?
TAKE trades at a trailing price-to-earnings (P/E) ratio of 76.59. The industry average P/E is 35.94. Its price-to-book (P/B) ratio is 10.86.
What is the return on equity (ROE) of TAKE?
TAKE has a return on equity (ROE) of 16.52%. Its return on capital employed (ROCE) is 15.37%.
Is TAKE a good stock to buy?
This page provides a data-driven analysis of TAKE LIMITED (TAKE), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.